Key facts for Q0237
- Billing unit
- 1 MG
- Inj, tocilizumab-anoh, hospi
- ASP payment limit
- $4.92
- October 2026; +0.0% vs July 2026
- Practitioner MUE
- none published
- CMS publishes no MUE for this code
- OPPS status
- SI L
- NCCI exposure
- no PTP pairs
- Coverage articles
- 0
- none list this code
TL;DR
HCPCS Q0237 is the Level II code for Injection, tocilizumab-anoh, for hospitalized adult patients with covid-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ecmo) only, 1 mg, billed per 1 MG. The Medicare Part B ASP payment limit for October 2026 is $4.92 per billing unit, up 0.0% from July 2026. Under OPPS it carries status indicator L. With a 1 mg billing unit, a single administration can be hundreds of units; the unit count on the claim must equal the milligrams given, and rounding rules for partial units follow the contractor's guidance. Other HCPCS codes whose descriptor names tocilizumab: Q5133 (biosimilar tocilizumab-bavi (Tofidence) from Organon LLC); Q5135 (biosimilar tocilizumab-aazg (Tyenne) from Fresenius Kabi USA, LLC); Q5156 (biosimilar tocilizumab-anoh (Avtozma) from Celltrion USA, Inc); Q0238 (tocilizumab-aazg); Q0234 (tocilizumab-bavi); Q0249 (for hospitalized adults and pediatric patients 2 years and older with COVID-19; the code whose CMS descriptor names no specific product). No current Billing and Coding Article lists Q0237, so coverage follows the FDA label, compendia and any applicable NCD.
Medicare Part B payment limit (ASP)
CMS sets the Part B payment limit for Q0237 at $4.92 per 1 MG for October 2026, derived from manufacturer average sales price plus 6%, compared with $4.92 in July 2026. Beneficiary coinsurance is 0%.
| Quarter | Payment limit | Per | Coinsurance |
|---|---|---|---|
| October 2026 | $4.92 | 1 MG | 0% |
| July 2026 | $4.92 | 1 MG | — |
NDC to HCPCS billing-unit conversion
The October 2026 ASP crosswalk lists no NDC for Q0237. Report the NDC from the product label and confirm the units conversion from the HCPCS descriptor (Injection, tocilizumab-anoh, for hospitalized adult patients with covid-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ecmo) only, 1 mg).
Medically Unlikely Edits (MUE)
CMS does not publish an MUE for Q0237 in the 2026 Q4 tables. Some MUE values are confidential and applied without publication, so unit limits can still deny; document the dose and the units calculation on every claim.
MUE for Q0237 in every setting opens the lookup with this code filled in, next to any other code on the same claim.
NCCI edits and add-on relationships
No active practitioner PTP pair lists Q0237 as a column-1 or column-2 code in v323r0. Drug supply codes are rarely bundled; the administration codes billed with them are where PTP edits usually apply.
The counts above are exposure, not answers for a specific claim. Check Q0237 against another code to see whether a given pair bundles, which code is paid and whether a modifier can separate them.
Q0237 is neither an add-on code nor a designated primary code in the 2026 Q4 NCCI add-on edit file.
Medicare coverage articles
No current Billing and Coding Article lists Q0237 in its HCPCS table. Coverage then follows the drug's FDA label, compendia and any National Coverage Determination; check the Medicare Coverage Database before administering off-label.
Hospital outpatient (OPPS) status
In the October 2026 OPPS Addendum B, Q0237 carries status indicator L. The OPPS status indicator reference explains how status L is paid.
Ambulatory surgical center (ASC) payment
In the October 2026 ASC Addendum BB (covered ancillary services), Q0237 carries payment indicator L1, which CMS defines as "Influenza vaccine; pneumococcal vaccine. Packaged item/service; no separate payment made". No separate national ASC rate is published for it.
Common denials for Q0237 and how to prevent them
For teams evaluating QuickIntell software
Evaluate a coding workflow for Q0237
Use the unit, NDC and edit questions in this reference to scope a QuickCode evaluation for qualified coder review, documentation clarification and the billing handoff. Confirm supported code sets, data inputs and reviewer responsibilities; the reference tables do not establish that a particular automated check or payer integration is available.
Optional software evaluation, not payer support or help with an individual claim. For coverage or payment decisions, use the official sources on this page. Do not include patient information in a demo booking or inquiry.
In QuickIntell research
- J codes by drug name: Every code for the same drug, generic or brand, in one A-Z index.
Frequently asked questions — HCPCS Q0237
What does HCPCS code Q0237 describe?
Q0237 is defined by CMS as "Injection, tocilizumab-anoh, for hospitalized adult patients with covid-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ecmo) only, 1 mg". Each billing unit represents 1 MG, so the units reported on the claim must equal the dose administered divided by that unit.
Is Q0237 a CPT code?
No. Q0237 is a HCPCS Level II code, the letter-plus-four-digit set CMS maintains for drugs such as tocilizumab-anoh; CPT codes are five-character codes maintained by the AMA. On a Part B claim Q0237 reports the drug itself in 1 mg units, and the administration is billed on its own line.
What is the Medicare reimbursement for Q0237 in October 2026?
The ASP-based payment limit is $4.92 per 1 MG, with 0% beneficiary coinsurance. The July 2026 limit was $4.92. Commercial payers use their own fee schedules.
Does Q0237 have NCCI bundling edits?
No active practitioner PTP pairs list Q0237 as a column-1 or column-2 code in the v323r0 release.
Q0237 vs Q5133: what is the difference?
Both are HCPCS Level II codes whose descriptor names tocilizumab. What sets Q5133 apart: biosimilar tocilizumab-bavi (Tofidence) from Organon LLC. Q0237 is billed per 1 mg, limit $4.92; Q5133 is billed per 1 mg, limit $4.706, MUE 1200. Report the code whose descriptor matches the product and setting in the record.
Q0237 vs Q5135: what is the difference?
Both are HCPCS Level II codes whose descriptor names tocilizumab. What sets Q5135 apart: biosimilar tocilizumab-aazg (Tyenne) from Fresenius Kabi USA, LLC. Q0237 is billed per 1 mg, limit $4.92; Q5135 is billed per 1 mg, limit $4.37, MUE 1200. Report the code whose descriptor matches the product and setting in the record.
Sources
Every figure on this page is taken from the CMS publications below, as released by the Centers for Medicare & Medicaid Services. Projection built 2026-11-16. Verify against the primary file before billing or contracting decisions. The reference methodology explains how each figure is computed from these files.
- HCPCS Level II alpha-numeric file, October 2026Version October 2026 · effective 2026-10-01 · file HCPC2026_OCT_ANWEB_09232026.txtSHA-256 c25240c63108756d…
- Medicare Part B Drug Payment Limit File, October 2026Version October 2026 · effective 2026-10-01 · file section 508 version of October 2026 Medicare Part B Payment Limit File 091626.csvSHA-256 508fba376a29e099…
- Medicare Part B Drug Payment Limit File, July 2026Version July 2026 · effective 2026-07-01 · file section 508 version of July 2026 Medicare Part B Payment Limit File updated 082026.csvSHA-256 13bb5b644b92b574…
- ASP NDC-HCPCS Crosswalk, October 2026Version October 2026 · effective 2026-10-01 · file section 508 version of October 2026 ASP NDC-HCPCS Crosswalk 091126.csvSHA-256 5cb78f0c2ee786ba…
- NCCI MUE table, practitioner services, effective 2026-10-01Version 2026 Q4 · effective 2026-10-01 · file MCR_MUE_PractitionerServices_Eff_10-01-2026.csvSHA-256 ef038efaf902b7bd…
- NCCI MUE table, facility services, effective 2026-10-01Version 2026 Q4 · effective 2026-10-01 · file MCR_MUE_OutpatientHospitalServices_Eff_10-01-2026.csvSHA-256 3af9f4e99cc587e2…
- NCCI MUE table, dme services, effective 2026-10-01Version 2026 Q4 · effective 2026-10-01 · file MCR_MUE_DMESupplierServices_Eff_10-01-2026.csvSHA-256 6fa4fbba852f7b74…
- NCCI PTP edits, practitioner, v323r0 (four files)Version v323r0 (2026 Q4) · effective 2026-10-01 · file ccipra-v323r0-f1.TXTSHA-256 7793c0b6686c1e22…
- NCCI Add-On Code edits, effective 2026-10-01Version 2026 Q4 · effective 2026-10-01 · file AOC_V2026Q4-F-MCR.xlsxSHA-256 eabb519623134549…
- OPPS Addendum B, October 2026Version October 2026 · effective 2026-10-01 · file 508-compliant-version-2026_October_Web_Addendum_B.09.28.26.csvSHA-256 6ad7393a318bf1b9…
- ASC Addendum BB (covered ancillary services), October 2026Version October 2026 · effective 2026-10-01 · file Oct 2026 ASC BB.txtSHA-256 63cdd7c72aba7a25…
- Medicare Coverage Database, current Billing and Coding Articles exportVersion MCD release 2026-11-12 · effective 2026-11-08 · file article.csvSHA-256 b475751458564786…
Disclaimer
This page is an operational reference compiled from CMS publications: the Medicare Part B drug payment limit and NDC crosswalk files, NCCI MUE and add-on edit tables, aggregate PTP statistics, OPPS Addendum B, ASC Addendum BB and the Medicare Coverage Database. Payment limits and rates are Medicare national amounts; commercial and Medicaid payers differ. CPT codes are shown as numbers only; CPT descriptors are copyright AMA. Nothing here is legal, clinical or billing advice.
Found a figure that does not match the CMS file? Report a data correction with the CMS file and the value you expected; the request reaches the editorial team through the contact form.